Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,658 matching trials from the live ClinicalTrials.gov search.
Conditions
Growth
Interventions
Control Infant Formula, Control Toddler Drink, Experimental Infant Formula, Experimental Toddler Drink, Human Milk, Human Milk Supplemental Formula, Human Milk Toddler Drink
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
0 Days to 14 Days
Enrollment
607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Glenwood, Arkansas • Hot Springs, Arkansas + 35 more
Conditions
X-linked Hypophosphatemia
Interventions
burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
5 Years to 12 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more
Conditions
Breast Cancer
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Interventions
Insulin-Like Growth Factor-1 (IGF-1), Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Gulf War Syndrome, Adult Growth Hormone Deficiency
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Conditions
Hemangioblastoma, Hippel Lindau Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Infants, Newborn
Interventions
Study Formula (SF), Comparator Formula (CF)
Other
Lead sponsor
ByHeart
Industry
Eligibility
0 Days to 14 Days
Enrollment
311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 24 more
Conditions
Growth Hormone Deficiency
Interventions
NuSpin, Somatropin
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
2 Years to 14 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more
Conditions
Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
16
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more
Conditions
Metastatic Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
Completed Phase 2 Interventional Results available

Hepatocyte Growth Factor to Improve Functioning in PAD

NCT03363165
Conditions
Peripheral Artery Disease
Interventions
VM202, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Fibrous Dysplasia Of Bone
Interventions
Burosumab
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
1 Year to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Cancer
Interventions
Protein restrictive diet
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Necrotizing Enterocolitis, Premature Birth
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 72 Hours
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Cincinnati, Ohio
Conditions
Pituitary Disorders, Adult Growth Hormone Deficiency
Interventions
growth hormone
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
23 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Conditions
Abdominal Obesity
Interventions
Tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioma
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

Effect of Weight Loss on Prostate Cancer Pathology

NCT00475982
Conditions
Obesity, Prostate Cancer
Interventions
Weight Loss, No Weight Loss Group
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
West Los Angeles, California
Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
Interventions
Palbociclib, Tamoxifen
Drug
Lead sponsor
Oana Danciu, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Chicago, Illinois • Lansing, Michigan • Minneapolis, Minnesota + 4 more
Conditions
Age Related Macular Degeneration
Interventions
Ranibizumab, Bevacizumab, Aflibercept, Control Group
Drug · Other
Lead sponsor
East Florida Eye Institute
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stuart, Florida
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Terminated No phase listed Observational

Monitoring Growth of Preterm Infants

NCT01869153
Conditions
Prematurity
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Sacramento, California